Benefits of moderate weight loss in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 3, 2010, Pages 186-194

  Fujioka, Ken ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Blood glucose; Diabetes mellitus; Diabetes mellitus type 2; Outcome assessment; Risk assessment; Therapeutics; Weight gain; Weight loss; Weight loss agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; CHLORPROPAMIDE; CHOLESTEROL; CREATININE; FATTY ACID; FLUOXETINE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INTERLEUKIN 6; MEGLITINIDE; METFORMIN; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEEDBACK SYSTEM; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; MENTAL DISEASE; METABOLIC REGULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 75649088159     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01155.x     Document Type: Review

References (76)

1. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687. (Lilly lecture) 1987.
2. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997, 4:177-269.
3. Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995, 3:366-377.
4. Crandall JP, Knowler WC, Kahn SE. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:382-393.
5. Hu FB, Manson JE, Stampfer MJ. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790-797.
6. Hussain A, Claussen B, Ramachandran A, Williams R. Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2007, 76:317-326.
7. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744-1766.
8. Mokdad AH, Ford ES, Bowman BA. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000, 23:1278-1283.
9. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993, 119(7 Pt 2):655-660.
10. Hamman RF, Wing RR, Edelstein SL. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102-2107.
11. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987, 147:1749-1753.
12. Wing RR, Marcus MD, Salata R, Epstein LH, Miaskiewicz S, Blair EH. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991, 151:1334-1340.
13. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
14. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999, 7:523-531.
15. Wolf AM, Siadaty M, Yaeger B. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc 2007, 107:1365-1373.
16. Leonetti F, Silecchia G, Iacobellis G. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 2003, 88:4227-4231.
17. Korner J, Inabnet W, Conwell IM. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006, 14:1553-1561.
18. Dixon JB, O'Brien PE, Playfair J. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
19. Pontiroli AE, Folli F, Paganelli M. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 2005, 28:2703-2709.
20. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
21. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009, 32((Suppl. 1)):S13-S61.
22. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13((Suppl. 1)):1-68.
23. Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol 2007, 62:220-233.
24. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002, 32((Suppl. 3)):24-34.
25. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008
26. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
27. Frayn KN. The glucose-fatty acid cycle: a physiological perspective. Biochem Soc Trans 2003, 31(Pt 6):1115-1119.
28. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
29. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998, 14:263-283.
30. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000, 49:677-683.
31. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
32. Norris SL, Zhang X, Avenell A. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005, (2:CD004095.
33. Trento M, Passera P, Tomalino M. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care 2001, 24:995-1000.
34. Zapotoczky H, Semlitsch B, Herzog G. A controlled study of weight reduction in type 2 diabetics treated by two reinforcers. Int J Behav Med 2001, 8:42-49.
35. Heller SR, Clarke P, Daly H. Group education for obese patients with type 2 diabetes: greater success at less cost. Diabet Med 1988, 5:552-556.
36. Korhonen T, Uusitupa M, Aro A. Efficacy of dietary instructions in newly diagnosed non-insulin-dependent diabetic patients. Comparison of two different patient education regimens. Acta Med Scand 1987, 222:323-331.
37. Uusitupa M, Litinen J, Siitonen O, Vanninen E, Pyorala K. The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. Diabetes Res Clin Pract 1993, 19:227-238.
38. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331-339.
39. Bertoni AG, Clark JM, Feeney P. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications 2008, 22:1-9.
40. Bray G, Gregg E, Haffner S. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006, 3:202-215.
41. Kelley DE. Action for health in diabetes: the Look AHEAD clinical trial. Curr Diab Rep 2002, 2:207-209.
42. Raynor HA, Jeffery RW, Ruggiero AM, Clark JM, Delahanty LM. Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. Diabetes Care 2008, 31:1299-1304.
43. Ribisl PM, Lang W, Jaramillo SA. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care 2007, 30:2679-2684.
44. Ryan DH, Espeland MA, Foster GD. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24:610-628.
45. Wing RR, Jakicic J, Neiberg R. Fitness, fatness, and cardiovascular risk factors in type 2 diabetes: Look AHEAD study. Med Sci Sports Exerc 2007, 39:2107-2116.
46. Pi-Sunyer X, Blackburn G, Brancati FL. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
47. Grunstein RR, Stenlof K, Hedner JA, Peltonen M, Karason K, Sjostrom L. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007, 30:703-710.
48. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
49. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J 2007, 335:1194-1199.
50. Sanofi-aventis to Discontinue all Clinical Trials with Rimonabant: Press Release. www.sanofi-aventis.us/live/us/en/index.jsp, Sanofi-aventis, Available from URL:, Accessed 20 December 2008.
51. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 1:CD004096.
52. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.
53. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005, 28:942-949.
54. Fujioka K, Seaton TB, Rowe E. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000, 2:175-187.
55. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med 1993, 119(7 Pt 2):737-743.
56. Blair SN, Shaten J, Brownell K, Collins G, Lissner L. Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial. Ann Intern Med 1993, 119(7 Pt 2):749-757.
57. Chaturvedi N, Fuller JH. Mortality risk by body weight and weight change in people with NIDDM. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1995, 18:766-774.
58. Hanson RL, McCance DR, Jacobsson LT. The U-shaped association between body mass index and mortality: relationship with weight gain in a Native American population. J Clin Epidemiol 1995, 48:903-916.
59. Lee IM, Paffenbarger RS. Is weight loss hazardous? Nutr Rev 1996, 54(4 Pt 2):S116-S124.
60. Lissner L, Odell PM, D'Agostino RB. Variability of body weight and health outcomes in the Framingham population. N Engl J Med 1991, 324:1839-1844.
61. Sorensen TI. Weight loss causes increased mortality: pros. Obes Rev 2003, 4:3-7.
62. Yang D, Fontaine KR, Wang C, Allison DB. Weight loss causes increased mortality: cons. Obes Rev 2003, 4:9-16.
63. Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. Diabetes Care 2004, 27:657-662.
64. Allison DB, Zannolli R, Faith MS. Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies. Int J Obes Relat Metab Disord 1999, 23:603-611.
65. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142.
66. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003, 2:33-47.
67. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group
68. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 3:CD002966.
69. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
70. Hollander P, Ratner R, Fineman M. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003, 5:408-414.
71. Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
72. Gerstein HC, Miller ME, Byington RP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
73. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.
74. Wing RR, Epstein LH, Nowalk MP, Koeske R, Hagg S. Behavior change, weight loss, and physiological improvements in type II diabetic patients. J Consult Clin Psychol 1985, 53:111-122.
75. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
76. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-1576.